If you completed either the EXHALE-2 or EXHALE-3 study, you may be eligible for this extension study.

During the first visit, a pregnancy test will be performed if you are a woman who can become pregnant.

You will need to review and sign consent documents to participate in the study.

You will receive dexpramipexole tablets that you will need to take by mouth.

The dosage is 150 mg twice daily.

The tablets are film-coated for easier swallowing.

Your health will be monitored through regular visits at weeks 16, 32, and 52.

During these visits, the following assessments will be performed:

– Blood tests to check your eosinophil levels (a type of white blood cell)

– Completion of an asthma control questionnaire

– Vital signs measurements

– Heart monitoring through ECG

– Laboratory tests

Any severe asthma episodes will be recorded throughout the 52-week period.

Your asthma control will be assessed using a questionnaire at specified visits.

Throughout the study, any health changes or side effects will be monitored and recorded.

Regular safety assessments will include blood tests, vital signs, and heart monitoring.

The study will conclude with a final visit after 52 weeks of treatment.

A final safety assessment will be performed during this visit.